Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology
Abstract Background Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblas...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13014-024-02566-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571431157760000 |
|---|---|
| author | Danny Jazmati Dennis Sohn Juliane Hörner-Rieber Nan Qin Edwin Bölke Jan Haussmann Rudolf Schwarz Niklas David Niggemeier Arndt Borkhardt Florian Babor Triantafyllia Brozou Melissa Felek Balint Tamaskovics Patrick Melchior Thomas Beez Beate Timmermann Marc Remke Stefanie Corradini Rémi Till Schulz Ronja-Linda Preugschas Wilfried Budach Christiane Matuschek |
| author_facet | Danny Jazmati Dennis Sohn Juliane Hörner-Rieber Nan Qin Edwin Bölke Jan Haussmann Rudolf Schwarz Niklas David Niggemeier Arndt Borkhardt Florian Babor Triantafyllia Brozou Melissa Felek Balint Tamaskovics Patrick Melchior Thomas Beez Beate Timmermann Marc Remke Stefanie Corradini Rémi Till Schulz Ronja-Linda Preugschas Wilfried Budach Christiane Matuschek |
| author_sort | Danny Jazmati |
| collection | DOAJ |
| description | Abstract Background Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease. Materials and methods Five distinct medulloblastoma cell lines (ONS76, UW228-3, DAOY, D283, D425) were exposed to varying radiation doses and fractionation schemes. In addition, ONS76 and UW228-3 stably overexpressing MYC were analyzed. Alpha/beta values, representing fractionation sensitivity, were quantified using the linear-quadratic model of radiation survival. Results The study unveiled elevated alpha/beta ratios across diverse medulloblastoma cell lines, with a weighted mean alpha/beta value of 11.01 Gy (CI: 5.23–16.79 Gy). Neither TP53 status nor the levels of MYC expression influenced fractionated radiosensitivity. Furthermore, differences in alpha/beta values cannot be correlated with molecular subgroups (p = 0.07) or radiosensitivity (SF2). Conclusion These in vitro findings strongly recommend normofractionated or hyperfractionated radiotherapy for paediatric medulloblastoma cases due to consistently high alpha/beta values across subgroups. Conversely, hypofractionated radiotherapy is not advisable within a curative approach. This study presents significant potential by enabling the estimation of radiobiological fractionations and dose effects in young, vulnerable patients, highlighting its importance for advancing patient-specific therapeutic strategies. |
| format | Article |
| id | doaj-art-2e294e21e1e54e0daa56a12e24f2a40a |
| institution | Kabale University |
| issn | 1748-717X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj-art-2e294e21e1e54e0daa56a12e24f2a40a2025-02-02T12:35:35ZengBMCRadiation Oncology1748-717X2025-01-0120111010.1186/s13014-024-02566-8Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncologyDanny Jazmati0Dennis Sohn1Juliane Hörner-Rieber2Nan Qin3Edwin Bölke4Jan Haussmann5Rudolf Schwarz6Niklas David Niggemeier7Arndt Borkhardt8Florian Babor9Triantafyllia Brozou10Melissa Felek11Balint Tamaskovics12Patrick Melchior13Thomas Beez14Beate Timmermann15Marc Remke16Stefanie Corradini17Rémi Till Schulz18Ronja-Linda Preugschas19Wilfried Budach20Christiane Matuschek21Department of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityLaboratory of Molecular Radiooncology, Clinic and Policlinic for Radiation Therapy and Radiooncology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University DüsseldorfDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University³Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of RT and Radiooncology, Outpatient Center, University Medical Center Hamburg-EppendorfDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University³Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University³Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University³Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University³Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of Radiation Oncology, Saarland University HospitalDepartment of Neurosurgery, Medical Faculty, Heinrich-Heine-UniversityDepartment of Particle Therapy, West German Proton Therapy Centre, University Hospital EssenDepartment of Pediatric Oncology and Hematology, Saarland University Medical CenterDepartment of Radiation Oncology, LMU UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityDepartment of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine UniversityAbstract Background Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease. Materials and methods Five distinct medulloblastoma cell lines (ONS76, UW228-3, DAOY, D283, D425) were exposed to varying radiation doses and fractionation schemes. In addition, ONS76 and UW228-3 stably overexpressing MYC were analyzed. Alpha/beta values, representing fractionation sensitivity, were quantified using the linear-quadratic model of radiation survival. Results The study unveiled elevated alpha/beta ratios across diverse medulloblastoma cell lines, with a weighted mean alpha/beta value of 11.01 Gy (CI: 5.23–16.79 Gy). Neither TP53 status nor the levels of MYC expression influenced fractionated radiosensitivity. Furthermore, differences in alpha/beta values cannot be correlated with molecular subgroups (p = 0.07) or radiosensitivity (SF2). Conclusion These in vitro findings strongly recommend normofractionated or hyperfractionated radiotherapy for paediatric medulloblastoma cases due to consistently high alpha/beta values across subgroups. Conversely, hypofractionated radiotherapy is not advisable within a curative approach. This study presents significant potential by enabling the estimation of radiobiological fractionations and dose effects in young, vulnerable patients, highlighting its importance for advancing patient-specific therapeutic strategies.https://doi.org/10.1186/s13014-024-02566-8Radiation therapyCancerPaediatric tumorBrain tumor |
| spellingShingle | Danny Jazmati Dennis Sohn Juliane Hörner-Rieber Nan Qin Edwin Bölke Jan Haussmann Rudolf Schwarz Niklas David Niggemeier Arndt Borkhardt Florian Babor Triantafyllia Brozou Melissa Felek Balint Tamaskovics Patrick Melchior Thomas Beez Beate Timmermann Marc Remke Stefanie Corradini Rémi Till Schulz Ronja-Linda Preugschas Wilfried Budach Christiane Matuschek Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology Radiation Oncology Radiation therapy Cancer Paediatric tumor Brain tumor |
| title | Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology |
| title_full | Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology |
| title_fullStr | Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology |
| title_full_unstemmed | Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology |
| title_short | Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology |
| title_sort | alpha beta values in pediatric medulloblastoma implications for tailored approaches in radiation oncology |
| topic | Radiation therapy Cancer Paediatric tumor Brain tumor |
| url | https://doi.org/10.1186/s13014-024-02566-8 |
| work_keys_str_mv | AT dannyjazmati alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT dennissohn alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT julianehornerrieber alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT nanqin alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT edwinbolke alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT janhaussmann alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT rudolfschwarz alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT niklasdavidniggemeier alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT arndtborkhardt alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT florianbabor alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT triantafylliabrozou alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT melissafelek alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT balinttamaskovics alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT patrickmelchior alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT thomasbeez alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT beatetimmermann alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT marcremke alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT stefaniecorradini alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT remitillschulz alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT ronjalindapreugschas alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT wilfriedbudach alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology AT christianematuschek alphabetavaluesinpediatricmedulloblastomaimplicationsfortailoredapproachesinradiationoncology |